These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 37925595)

  • 1. Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
    Li N; Zheng X; Gan J; Zhuo T; Li X; Yang C; Wu Y; Qin S
    Chin Med J (Engl); 2023 Nov; 136(21):2562-2572. PubMed ID: 37925595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment.
    Wang Y; Yang M; Tao M; Liu P; Kong C; Li H; Chen Y; Yin X; Yan X
    Int Immunopharmacol; 2021 Oct; 99():108031. PubMed ID: 34358857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
    Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
    Front Oncol; 2022; 12():976224. PubMed ID: 36185176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhang N; Chang J; Liu P; Tian X; Yu J
    Front Immunol; 2024; 15():1400262. PubMed ID: 38915398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
    Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
    Front Immunol; 2022; 13():968729. PubMed ID: 35967438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
    Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
    Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
    J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
    Guo H; Li Y; Lin J; Li D; Yang J; Wang J; Mao J; Wang Y; Yan X
    Int Immunopharmacol; 2024 Mar; 129():111611. PubMed ID: 38325047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Li LL; Yu CF; Xie HT; Chen Z; Jia BH; Xie FY; Cai YF; Xue P; Zhu SJ
    Cancer Med; 2023 May; 12(10):11211-11233. PubMed ID: 37161541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis.
    Tian BW; Han CL; Wang HC; Yan LJ; Ding ZN; Liu H; Mao XC; Tian JC; Xue JS; Yang LS; Tan SY; Dong ZR; Yan YC; Wang DX; Li T
    Clin Exp Metastasis; 2023 Aug; 40(4):255-287. PubMed ID: 37308706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of
    Ling T; Zhang L; Peng R; Yue C; Huang L
    Front Immunol; 2022; 13():1014063. PubMed ID: 36466905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Li F; Zhai S; Lv Z; Yuan L; Wang S; Jin D; Yi H; Fu L; Mao Y
    Front Oncol; 2022; 12():968517. PubMed ID: 36439448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer.
    Zhang Y; Chen S; Chen H; Li W
    Cancer Med; 2023 Jan; 12(1):38-48. PubMed ID: 35702873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis.
    Xu H; Ming P; Zhao Z; Zhao N; Zhou D; Tang X; Cao D
    Integr Cancer Ther; 2023; 22():15347354231164584. PubMed ID: 36998207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of baseline metabolic tumor volume for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhu K; Su D; Wang J; Cheng Z; Chin Y; Chen L; Chan C; Zhang R; Gao T; Ben X; Jing C
    Front Oncol; 2022; 12():951557. PubMed ID: 36147904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.